This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (NCT01531998), a na phase 1, phase 2 study. The primary outcome is Maximum Tolerated Dose (MTD) of Siltuximab.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT01531998 |
| Phase | Phase 1, Phase 2 |
| Condition | Myeloma |
| Allocation | Not applicable (single group) |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 14 |
| Arms in the primary outcome | n/a |
| Lead sponsor | M.D. Anderson Cancer Center |
| Results posted | Yes |
2. Clinical Question
Population
The study concerned people with newly diagnosed, previously untreated multiple myeloma requiring systemic chemotherapy. The title identifies the intended population as transplant eligible. The registry record lists Myeloma as the condition. It does not report further eligibility details in the information available for this analysis.
Intervention
The regimen combined siltuximab with lenalidomide, bortezomib and dexamethasone. The listed induction schedule includes lenalidomide 25 mg orally on Days 1-14; bortezomib 1.3 mg/m2 intravenously on Days 1, 4, 8 and 11; dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12; and siltuximab 11 mg/kg intravenously on Day 1. The record also lists questionnaires.
Comparator
There was no separate comparator group. This was a single-group study, with no random allocation and no masking. Accordingly, the observations describe outcomes within the treatment group; they do not provide a randomized comparison against another treatment or a control condition.
Primary question
The primary question was what maximum tolerated dose of siltuximab could be used in combination with the other listed drugs, with the primary outcome assessed over 21 days. The study also set out to examine safety, and a secondary outcome concerned the number of participants with a response. The registry record defines the primary outcome but does not report its observed value or the response result.
3. Trial Design
This was an open-label, single-arm phase 1b/2 study sponsored by M.D. Anderson Cancer Center. The registry record lists enrollment of 14 and a completed status. The recorded start was 2012-05 and primary completion was 2014-05. With one treatment group and no masking, the design is suited to describing the regimen administered and monitoring outcomes within that group; it does not establish a treatment effect relative to a concurrent control.
The intervention combined lenalidomide, bortezomib, dexamethasone and siltuximab. The available induction description lists the doses, routes and treatment days for these drugs. It also describes continuing induction in the event of delayed transplant, but that part of the schedule is truncated in the registry record, so its complete conditions and duration are not reported there. Questionnaires are listed as an additional intervention, without further detail in the record summarized for this analysis.
The study’s stated goal was to identify the highest tolerable siltuximab dose in the combination and examine safety. The primary outcome was maximum tolerated dose, defined using dose-limiting toxicity during a 21-day timeframe. The registry record gives a toxicity-based decision rule but does not report the dose-level results needed to identify the observed maximum tolerated dose. It also does not report the number of dose-limiting toxicities or a dose-by-dose account.
A response outcome is listed as secondary. Its observed result is not reported in the registry record. The single-arm structure matters when interpreting all outcomes: event counts can describe what was observed among participants in the regimen group, but without a control group they cannot isolate the regimen’s effect from other explanations. The record does not report the full protocol or additional operational details such as the dose-escalation path.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Of the fourteen participant enrolled, three were screen failures and not enrolled on the study.
Overall Study
| Stage | Siltuximab + Bortezomib + Lenalidomide |
|---|---|
| STARTED | 11 |
| COMPLETED | 8 |
| NOT COMPLETED | 3 |
Reasons for not completing this period:
| Reason | Siltuximab + Bortezomib + Lenalidomide |
|---|---|
| Withdrawal by Subject | 3 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Siltuximab + Bortezomib + Lenalidomide |
|---|---|---|
| Participants analysed | 11 | |
| Age, Continuous | years | 62 (47 to 73) |
| Sex: Female, Male: Female | Participants | 7 |
| Sex: Female, Male: Male | Participants | 4 |
| Region of Enrollment: United States | participants | 11 |
6. Primary Endpoint
The registry lists the primary outcome as Maximum Tolerated Dose (MTD) of Siltuximab, measured over 21 days.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | mg/kg |
| Endpoint classification | not reduced to a single comparison |
The primary outcome is the maximum tolerated dose of siltuximab, expressed in mg/kg. The registry record defines it through dose-limiting toxicity (DLT) during a 21-day timeframe. It states that, at the first dose level, if greater than 1 out of 3 patients or greater than 1 out of 6 patients experience a DLT, the dose level exceeds the maximum tolerated dose. DLT is defined as toxicity graded according to the NCI-Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
In general, a maximum tolerated dose endpoint is used in early-phase research to characterize a dose boundary based on tolerability under the study’s specified toxicity rules. It is not itself a measure of comparative benefit. Its interpretation depends on which doses were tested, how participants were assigned to dose levels, what toxicities occurred, and how those events were graded and attributed. Those dose-level outcomes are not reported in the registry record, so the observed maximum tolerated dose cannot be stated from this information.
The outcome definition supplies a decision rule, not the result of applying that rule. The record also does not report the individual DLT observations or the dose level at which the rule was met. As a result, the endpoint’s intended meaning can be described, but its numerical value and the evidence supporting it remain unavailable in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record describes an early-phase study of a four-drug regimen in newly diagnosed multiple myeloma. Its primary aim was dose and safety characterization, rather than a comparison of the regimen against another treatment. The study is listed as open-label and single-arm, with enrollment of 14. These design features define what its results can establish: observations can characterize events recorded in the study group, but there is no randomized control group for estimating a relative treatment effect.
The primary outcome is defined as the maximum tolerated dose of siltuximab, with DLT assessed over 21 days under the stated CTCAE version 4.0 grading framework. The observed MTD, dose-level enrollment, DLT counts and dose-escalation results are not reported in the registry record. Consequently, the central primary result cannot be evaluated from the record. A prespecified definition alone does not reveal whether the threshold was crossed or which dose was considered tolerable.
The record lists a secondary outcome, the number of participants with response, but does not report its result. It also lists two outcome measures overall, while no analysis results are reported in the registry record. No estimate of response frequency, uncertainty interval, or inferential test can therefore be described. The absence of a reported result is not evidence that no responses or toxicities occurred; it means the registry record does not give the result needed to assess them.
Safety information gives a separate, limited view. In the listed treatment group, 3 of 11 participants at risk were affected by serious adverse events, and 11 of 11 at risk were affected by other adverse events. The most frequently listed serious adverse event terms are lung infection at 18.2% and hematuria at 9.1%. These event summaries should be read as descriptive reports, not as estimates of comparative risk. The registry record does not report a control group, a causal comparison, or the information needed to attribute any particular event to a specific drug in the combination.
In general, estimates from small groups are imprecise, and descriptive counts may be sensitive to the experience of individual participants. That is especially relevant when an outcome is based on uncommon toxicities or when the aim is dose finding. The registry record does not report confidence intervals or a statistical model for the primary outcome. It therefore does not support a precise estimate of toxicity risk or a robust comparison across doses. The posted safety counts and event terms are useful as recorded observations, but they do not answer whether the regimen is safer or more effective than an alternative.
The most defensible reading is consequently narrow: the registry describes the study design, defines a dose-limiting toxicity rule, and reports some adverse-event counts, but it does not report the primary MTD result or the secondary response result. Conclusions about efficacy, comparative safety, or the dose selected by the study are not established by the reported information.
9. Statistical Methods Explained
What does the single-arm design allow?
The study has one treatment group, no random allocation and no masking. In general, a single-arm study can describe what happened among participants receiving the regimen, including observed toxicities and responses. It does not create a concurrent comparison that can separate the regimen’s effects from the natural course of disease, background care, participant characteristics or other influences. Any observed outcome is therefore descriptive in relation to this design, rather than a randomized estimate of the difference caused by treatment.
Open-label means the study was not masked. In general, knowledge of treatment can influence assessment or reporting, particularly for outcomes involving judgment. The primary outcome uses toxicity grades, and the registry record identifies the CTCAE version used, but it does not describe independent review, assessor masking or adjudication procedures. Those procedures are not reported in the registry record.
How should the MTD rule be understood?
The endpoint uses a threshold rule based on DLTs over 21 days. In general, a rule of this kind turns observed toxicities at a dose level into a dose-selection decision. The particular rule and the toxicity grading framework matter: changing the observation period, toxicity definition or threshold can change which dose is classified as exceeding the MTD. The registry record specifies the threshold language and CTCAE version 4.0, but does not report the actual toxicities or the decision reached.
In general, dose-finding results depend on the sequence and number of participants treated at each dose, whether dose escalation was paused or modified, and how toxicity was assessed. The registry record does not report the tested dose levels, assignments by dose, escalation details or the dose-level DLT counts. Thus the MTD cannot be reconstructed from the stated rule alone. The rule is the method for interpreting observations; it is not a substitute for those observations.
What does an event count communicate?
A count of participants affected is a descriptive summary of observed events in a defined group. In general, a count does not by itself show how precisely the underlying event frequency is estimated. It also does not establish causation. Attribution requires clinical and methodological information beyond the fact that an event was recorded during a study. In this record, the serious adverse-event summary reports 3 affected among 11 at risk, and the other adverse-event summary reports 11 affected among 11 at risk. The record’s listed serious event terms include lung infection and hematuria, with the stated percentages. No comparative event rates are available because the design has no control group.
Over-dispersion is a general statistical concern when event variation is greater than a simple model assumes. In general, if a model underestimates variation, uncertainty intervals can be too narrow and statistical tests can be too optimistic. The registry record does not report a statistical model for these event summaries, so it is not possible to assess whether over-dispersion was considered. For small safety groups, the actual event counts and definitions are often more informative than an unsupported model-based precision claim.
What can confidence intervals and tests add?
In general, a confidence interval communicates the range of values reasonably compatible with data and a specified statistical procedure. It conveys precision, not the probability that a particular fixed value is correct. A hypothesis test assesses compatibility with a null model under its assumptions; a p-value is not the probability that the treatment works or that the null hypothesis is true. The registry record does not report confidence intervals, p-values or inferential analyses for the outcomes. No such inferential result should be inferred from the event counts alone.
The record lists no analysis results. It also does not report the statistical analysis plan, model specification, handling of repeated events, or whether any analyses were adjusted for participant characteristics. In general, such choices can matter because they determine the question an estimate answers and how its uncertainty is calculated. Without the analysis details and results, the primary endpoint’s precision and the statistical treatment of secondary outcomes are unknown.
How should planning calculations be distinguished from trial evidence?
In general, a sample-size calculation is a planning exercise that describes the size of a future study under chosen assumptions. It is not a measure of the probability that the present study found a real effect, and it is not observed power. Any planning illustrations associated with these data use a two-sided significance level of 0.05, equal allocation between two arms and a normal approximation, with the target effect expressed as a fraction of the observed effect. Those are illustration assumptions, not a reported design for this single-arm trial. In particular, the assumed equal allocation between two arms does not describe this study’s actual one-group structure.
Planning calculations based on an observed effect can also be unstable when the observed effect is imprecise. In general, an uncertain estimate can lead to an uncertain planning target; a planning result should not be read as validation of the original effect. The registry record does not report a sample-size justification for this trial, so no claim about its planned statistical power or design rationale is warranted.
10. Multiplicity, Missing Data and Analysis Populations
The registry record lists the maximum tolerated dose of siltuximab as the primary outcome and lists Number of Participants With Response as a secondary outcome. It does not report a multiplicity strategy. In general, when several outcomes or statistical tests are examined, multiplicity procedures can limit the chance of false-positive findings across a family of tests. Whether such adjustment is needed depends on the prespecified inferential goals and analysis plan, neither of which is reported in sufficient detail. Because no inferential results are reported, the effect of any multiplicity approach cannot be assessed.
Missing-data handling is not reported in the registry record. The record does not describe whether outcome data were incomplete, how incomplete observations were treated, or whether participants were included in the analyses according to a defined analysis population. It also does not report an analysis population definition for the primary or secondary outcome. These omissions matter because exclusions or incomplete follow-up can affect both the estimate and its interpretation, especially in a small early-phase study.
The registry lists enrollment of 14, while the adverse-event summary reports 11 participants at risk for its group. The registry record does not explain the relationship between those figures, so no reason for the difference should be inferred. The serious adverse-event summary reports 3 affected among 11 at risk; the other adverse-event summary reports 11 affected among 11 at risk. The registry record does not report deaths. It also does not describe missingness or follow-up for the response outcome. These reporting gaps limit the ability to judge completeness and to reconstruct the analyses.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Siltuximab + Bortezomib + Lenalidomide | 3 | 11 | 27.3% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Siltuximab + Bortezomib + Lenalidomide | 11 of 11 |
Most frequent serious adverse event terms
| Event term | Organ system | Siltuximab + Bortezomib + Lenalidomide |
|---|---|---|
| Lung infection | Infections and infestations | 2 of 11 |
| Hematuria | Renal and urinary disorders | 1 of 11 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Siltuximab + Bortezomib + Lenalidomide |
|---|---|---|
| Anemia | Blood and lymphatic system disorders | 11 of 11 |
| Neutropenia | Blood and lymphatic system disorders | 11 of 11 |
| Thrombocytopenia | Blood and lymphatic system disorders | 11 of 11 |
| Leukopenia | Blood and lymphatic system disorders | 11 of 11 |
| Fatigue | General disorders | 11 of 11 |
| Lymphopenia | Blood and lymphatic system disorders | 10 of 11 |
| Constipation | Gastrointestinal disorders | 10 of 11 |
| Edema: Limbs | General disorders | 10 of 11 |
| Hypocalcemia | Metabolism and nutrition disorders | 8 of 11 |
| Dizziness | Nervous system disorders | 8 of 11 |
Serious events with the highest arm-level rate: lung infection (18.2%), hematuria (9.1%).
The adverse-event record lists one treatment group, Siltuximab + Bortezomib + Lenalidomide. For serious adverse events, 3 of 11 participants at risk were affected; for other adverse events, 11 of 11 participants at risk were affected. The serious-event terms listed most prominently are lung infection at 18.2% and hematuria at 9.1%. These are the registry’s reported summaries; they do not establish that any event was caused by a particular study drug.
In general, serious adverse events are a classification of event seriousness and should not be conflated with the severity grade of every event. The registry record does not give event-level details, duration, recurrence, timing, or attribution for these summaries. It does not report deaths. The terms and counts are therefore best read as descriptive safety observations, not as a full account of each participant’s experience.
The denominator is important when reading an event count: the adverse-event group identifies 11 participants at risk, while the overall enrollment is listed as 14. The reason these figures differ is not reported in the registry record. The design contains no comparator group, so the observed counts cannot quantify excess risk relative to another regimen or usual care.
12. What the Result Does, and Does Not, Mean
The registry record establishes that this was an open-label, single-arm phase 1b/2 study intended to examine the safety of a combination regimen and identify a maximum tolerated dose of siltuximab. It specifies a DLT definition, a 21-day assessment timeframe and the toxicity grading framework. It also reports adverse-event summaries for the treatment group. Those features explain the study’s clinical and statistical purpose, but they do not supply the primary endpoint result.
The MTD value is not reported in the registry record. The dose-level outcomes and DLT counts needed to understand how the rule was applied are also not reported. The secondary response outcome is listed, but its observed result is not reported. Thus, the record does not establish which dose was selected, how many participants responded, or the precision of either outcome.
In general, a finding from a single-arm study cannot be interpreted as a controlled estimate of treatment benefit or harm. Without a comparator, outcomes may reflect factors other than the regimen. The reported serious and other adverse-event counts describe what was recorded in the group, but they do not show how those counts compare with a different treatment. They also do not, by themselves, establish drug-specific causation.
The study’s completed status should not be confused with complete public reporting of all results. The record does not give the missing outcome values, analysis details, or a complete explanation of the participant counts used in the safety summary. The appropriate conclusion is limited to the design, endpoint definition and descriptive safety figures that are reported. Claims about effectiveness, comparative safety or a selected MTD go beyond the information in the registry record.
13. Why This Trial Matters Statistically
This trial illustrates a central statistical distinction in early-phase research: defining an outcome is not the same as reporting its result. The registry record describes a toxicity-based rule for maximum tolerated dose, including the assessment timeframe and grading framework. Without dose-level observations and the resulting decision, however, readers cannot determine which dose met the study’s criterion or how much evidence supports that choice.
The single-arm structure is also important. Dose-finding and safety characterization can be pursued without a concurrent control, but the resulting observations answer a narrower question than a randomized comparison. Counts within the treatment group do not estimate how outcomes would have differed under another regimen. This distinction helps prevent descriptive safety information from being mistaken for causal or comparative evidence.
Reporting denominators is essential for interpreting event summaries. The record gives 11 participants at risk in the adverse-event group and lists enrollment of 14, without explaining the difference. The record also gives serious and other adverse-event counts, but does not describe the analysis population or missing-data approach. Those gaps limit reproducibility and make it difficult to assess the completeness of follow-up.
Finally, a phase 1b/2 designation and a clearly stated endpoint do not replace reported analyses. Readers need the observed outcome, the dose-level information and sufficient methods to understand how the endpoint was derived. This record is statistically informative about the intended question and some safety reporting, while its unreported primary and response results constrain the conclusions that can be drawn.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most consequential limitation of the registry record is that it defines the primary outcome but does not report the observed maximum tolerated dose. Dose-level enrollment, DLT counts and the escalation results are also not reported. This prevents an independent assessment of the dose-selection rule and leaves the study’s central result unavailable.
The response outcome is listed, but its result is not reported. The registry record does not report confidence intervals, p-values, statistical models or a complete statistical analysis plan. It also does not report the handling of missing data, the analysis populations, or the relationship between enrollment of 14 and the 11 participants at risk in the adverse-event summary. No explanation for that difference should be assumed.
Safety information is limited to group-level counts and selected serious-event terms. The record does not provide event timing, duration, recurrence, participant-level context or attribution to individual components of the combination. It does not report deaths. Without a comparator group, even complete within-group event reporting would not establish comparative safety.
The intervention description is incomplete: the induction schedule includes a truncated statement concerning continued therapy in the event of delayed transplant. The record therefore does not provide all treatment-duration details in the available description. Additional eligibility criteria and operational details of dose assignment are not reported in the registry record. Together, these reporting limits restrict reconstruction of the study methods and interpretation of the available outcomes.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) — NCT01531998.
- Registry record last updated 2015-06-19; status last verified 2015-06.
- Results first posted 2015-06-19.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes a completed, open-label, single-arm phase 1b/2 study sponsored by M.D. Anderson Cancer Center, with enrollment of 14. It evaluated siltuximab in combination with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma. Its primary outcome was maximum tolerated dose of siltuximab, defined using dose-limiting toxicity over 21 days and CTCAE version 4.0.
The observed MTD and the response result are not reported in the registry record. Safety summaries list 3 of 11 participants at risk affected by serious adverse events and 11 of 11 affected by other adverse events. Lung infection at 18.2% and hematuria at 9.1% are the listed serious-event terms. The record does not provide a comparator, analysis details, missing-data methods or an explanation of the adverse-event denominator.